

# Developing an Antimicrobial Strategy for Sepsis in Malawi

-

Thesis submitted in accordance with the requirements of the Liverpool School of Tropical Medicine for the degree of Doctor in Philosophy by Joseph Michael Lewis

August 2019



# Contents

<b>Preface</b>	<b>9</b>
<b>1 Introduction</b>	<b>11</b>
1.1 Chapter Overview . . . . .	13
1.2 Sepsis in sub-Saharan Africa . . . . .	13
1.3 ESBL-E in sub-Saharan Africa . . . . .	13
1.4 Conclusions . . . . .	13
1.5 Thesis overview . . . . .	13
1.6 Appendix . . . . .	13
1.7 References . . . . .	13
<b>2 Methods</b>	<b>15</b>
2.1 Chapter Overview . . . . .	17
2.2 Study site . . . . .	17
2.3 Clinical Study . . . . .	17
2.4 Diagnostic Laboratory Procedures . . . . .	17
2.5 Molecular methods . . . . .	17
2.6 Bioinformatics . . . . .	17
2.7 Statistical Analysis . . . . .	17
2.8 Study Team . . . . .	17
2.9 Data Collection and Storage . . . . .	17
2.10 Ethical Approval, Consent and Participant Remuneration . . . . .	17
<b>3 <i>Mycobacterium tuberculosis</i> BSI: an IPD meta analysis</b>	<b>19</b>
<b>4 A clinical and microbiological description of sepsis in Blantyre, Malawi</b>	<b>21</b>
4.1 Chapter overview . . . . .	22
4.2 Introduction and chapter aims . . . . .	22
4.3 Aims and Methods . . . . .	22

4.4	Results . . . . .	22
4.5	Discussion . . . . .	22
4.6	Conclusions and further work . . . . .	22
4.7	Appendix . . . . .	22
<b>5</b>	<b>Longitudinal ESBL-E carriage in Malawian adults in health and disease</b>	<b>23</b>
5.1	Chapter Overview . . . . .	23
5.2	Introduction and chapter aims . . . . .	23
5.3	Methods . . . . .	23
5.4	Results . . . . .	23
5.5	Discussion . . . . .	32
5.6	Conclusions and further work . . . . .	32
<b>6</b>	<b>Whole genome sequencing of ESBL <i>E. coli</i> carriage isolates</b>	<b>33</b>
6.1	Chapter overview . . . . .	35
6.2	Methods . . . . .	35
6.3	Results . . . . .	35
6.4	Discussion . . . . .	35
6.5	Appendix . . . . .	35
<b>7</b>	<b>Gut mucosal carriage of ESBL-E in Blantyre, Malawi</b>	<b>37</b>
	<b>References</b>	<b>39</b>

# List of Tables

5.1	Participant Characteristics . . . . .	26
5.2	Antimicrobial and hospital exposure stratified by arm . . . . .	31



# List of Figures

5.1	Missing samples and variation in sample collection time . . . . .	24
5.2	ESBL carriage study recruitment and follow up. . . . .	25
5.3	Hospital and antibacterial exposure of participants . . . . .	30
5.4	Cumulative antibacterial exposure for baseline unexposed inpatients. . . . .	32





# Preface

Placeholder



# Chapter 1

## Introduction

Placeholder



## 1.1 Chapter Overview

## 1.2 Sepsis in sub-Saharan Africa

### 1.2.1 Search strategy

### 1.2.2 Defining sepsis

### 1.2.3 Applicability of sepsis-3 definitions in sub-Saharan Africa

### 1.2.4 Sepsis epidemiology in sub-Saharan Africa

#### 1.2.4.1 Incidence

#### 1.2.4.2 Risk factors: the sepsis population in sub-Saharan Africa

#### 1.2.4.3 Outcomes

### 1.2.5 Sepsis aetiology in sub-Saharan Africa

#### 1.2.5.1 Bacterial zoonoses, Rickettsioses and arboviruses

#### 1.2.5.2 HIV opportunistic infections: PCP, histoplasmosis and cryptococcal disease

### 1.2.6 Sepsis management

#### 1.2.6.1 Early goal directed therapy

#### 1.2.6.2 Evidence to guide antimicrobial therapy in sSA

#### 1.2.6.3 Evidence to guide intravenous fluid therapy in sub-Saharan Africa

## 1.3 ESBL-E in sub-Saharan Africa

### 1.3.1 Search strategy

### 1.3.2 Introduction: definition and classification of ESBL-E

### 1.3.3 Global molecular epidemiology of ESBL-E: an overview

#### 1.3.3.1 1980s-1990s: First identification of ESBL in nosocomial pathogens

#### 1.3.3.2 1990s-2010s: Emergence and globalisation of CTX-M



## Chapter 2

# Methods

Placeholder





## 2.1 Chapter Overview

## 2.2 Study site

### 2.2.1 Malawi

### 2.2.2 Queen Elizabeth Central Hospital

### 2.2.3 Participating Laboratories

#### 2.2.3.1 Malawi-Liverpool-Wellcome Clinical Research Programme

#### 2.2.3.2 Malawi College of Medicine Tuberculosis Laboratory

#### 2.2.3.3 Wellcome Trust Sanger Institute

## 2.3 Clinical Study

### 2.3.1 Entry Criteria

### 2.3.2 Study Visits and Patient Sampling

#### 2.3.2.1 Enrollment assessment and first six hours

#### 2.3.2.2 Subsequent visits

#### 2.3.2.3 Blood, urine, and stool, sputum and CSF collection

#### 2.3.2.4 Imaging: chest x-ray and ultrasound scanning

### 2.3.3 Outcomes and sample size calculations

## 2.4 Diagnostic Laboratory Procedures

### 2.4.1 Point of care diagnostics

### 2.4.2 Laboratory diagnostics

#### 2.4.2.1 Haematology and biochemistry

#### 2.4.2.2 Aerobic blood and CSF culture

#### 2.4.2.3 Mycobacterial blood culture

#### 2.4.2.4 Sputum Xpert



## Chapter 3

# *Mycobacterium tuberculosis* BSI: an IPD meta analysis



## Chapter 4

# A clinical and microbiological description of sepsis in Blantyre, Malawi

Placeholder

## 4.1 Chapter overview

## 4.2 Introduction and chapter aims

## 4.3 Aims and Methods

## 4.4 Results

### 4.4.1 Study population

### 4.4.2 Symptoms and health-seeking behaviour

### 4.4.3 Admission physiology and laboratory investigations

### 4.4.4 Aetiology

### 4.4.5 Treatment

### 4.4.6 Outcome

### 4.4.7 Determinants of mortality

## 4.5 Discussion

### 4.5.1 Demographics and outcome: significant longer-term mortality

### 4.5.2 Aetiology: TB dominates as a cause of sepsis

### 4.5.3 Determinants of 28-day mortality: an expanded role for TB therapy?

### 4.5.4 Limitations

## 4.6 Conclusions and further work

## 4.7 Appendix

## Chapter 5

# Longitudinal ESBL-E carriage in Malawian adults in health and disease

### 5.1 Chapter Overview

### 5.2 Introduction and chapter aims

### 5.3 Methods

### 5.4 Results

#### 5.4.1 Study population

In total, 425 participants were recruited to the study between 19th February 2017 and 2nd October 2018; 225 participants with sepsis (arm 1), 100 inpatients without antimicrobial exposure at baseline (arm 2) and 100 community members (arm 3). Flow of participants through the study is shown in Figure 5.2. It was often challenging to collect stool samples from participants but 87% (1416/1631) eligible patient-visits resulted in the collection of a stool sample. Drop out from the study and failure to collect stool samples were similar in arm 1 and 2 and with no apparent systematic bias, but both drop out and missing samples were less frequent in arm 3 (Figure 5.1A). There was significant variation in the timing of stool sample collection, with a distribution around the ostensible collation day (Figure 5.1B).




Figure 5.1: A: Missing stool samples stratified by arm and visit. Bar height at a given visit represents the number of eligible participants, coloured by successful sample collection (blue) or failure to collect a sample (red). B: Distribution of actual day of sample collection for ostensible day 7, 28, 90 and 180 samples showing considerable variation.

The baseline characteristics of the enrolled participants are shown in Table 5.1. There were some important differences between the arms of the study: despite matching on age and sex, antimicrobial-unexposed participants were older. They were also less likely to be HIV-infected than participants with sepsis (13% [12/89] of those with known HIV status were HIV-infected versus 67% [143/213] with sepsis), and less likely to have been treated for TB. Sepsis participants were more likely to have received antimicrobials or been hospitalised in the previous 4 weeks. In the community arm of the study, there were a high proportion of participants (60% [60/100]) with an unknown HIV status, and there were some differences in toilet facilities, water sources, cooking fuel and presence of animals at home across the three groups.






Figure 5.2: Study recruitment and follow up. At each time point *eligible participants* refers to participants who are known to be alive and have not withdrawn from the study by that time point, and *samples collected* refers to patients from whom a stool sample was successfully collected for that visit.

Table 5.1: Participant Characteristics

Variable	Sepsis	Inpatient	Community	p	Total
<b>Demographics</b>					
Age (yr)	<b>35.9 (27.8-43.5)</b>	<b>40.4 (29.1-48.3)</b>	<b>32.5 (24.0-38.4)</b>	<b>&lt;0.001</b>	<b>35.6 (26.9-43.9)</b>
Male sex	114/225 (51%)	51/100 (51%)	40/100 (40%)	0.533	205/425 (48%)
<b>HIV/TB status</b>					
HIV Reactive	<b>143/225 (64%)</b>	<b>12/100 (12%)</b>	<b>18/100 (18%)</b>	<b>&lt;0.001</b>	<b>173/425 (41%)</b>
HIV Non Reactive	<b>70/225 (31%)</b>	<b>77/100 (77%)</b>	<b>22/100 (22%)</b>	<b>&lt;0.001</b>	<b>169/425 (40%)</b>
HIV Unknown	<b>12/225 (5%)</b>	<b>11/100 (11%)</b>	<b>60/100 (60%)</b>	<b>&lt;0.001</b>	<b>83/425 (20%)</b>
Ever treated for TB	<b>37/225 (16%)</b>	<b>5/100 (5%)</b>	<b>4/100 (4%)</b>	<b>0.002</b>	<b>46/425 (11%)</b>
Of those, current TB treatment	10/37 (27%)	0/5 (0%)	4/4 (100%)	0.098	14/46 (30%)
<b>ART status*</b>					
Current ART*	117/143 (82%)	9/12 (75%)	18/18 (100%)	0.859	144/173 (83%)
Months on ART	28.7 (3.7-72.6)	35.1 (2.9-79.8)	31.5 (13.0-79.9)	0.693	29.5 (3.8-72.8)
ART regimen: EFV/3TC/TDF	110/117 (94%)	8/9 (89%)	17/18 (94%)	1.000	135/144 (94%)
<b>ART status</b>					
Current CPT <sup>†</sup>	98/141 (70%)	5/12 (42%)	7/18 (39%)	0.328	110/171 (64%)
<b>Healthcare exposure last 4wk</b>					
Antibiotics	<b>60/225 (27%)</b>	<b>0/100 (0%)</b>	<b>0/100 (0%)</b>	<b>&lt;0.001</b>	<b>60/425 (14%)</b>
Hospitalised	<b>18/225 (8%)</b>	<b>1/100 (1%)</b>	<b>0/100 (0%)</b>	<b>0.001</b>	<b>19/425 (4%)</b>
<b>Tobacco/alcohol use</b>					
Never tobacco	196/225 (87%)	93/100 (93%)	90/100 (90%)	0.929	379/425 (89%)
Ex tobacco	17/225 (8%)	6/100 (6%)	2/100 (2%)	0.180	25/425 (6%)
Current tobacco	12/225 (5%)	1/100 (1%)	8/100 (8%)	0.070	21/425 (5%)
Current alcohol	51/225 (23%)	16/100 (16%)	18/100 (18%)	0.502	85/425 (20%)
<b>Education</b>					
Primary incomplete or complete	97/225 (43%)	50/100 (50%)	42/100 (42%)	0.739	189/425 (44%)
Some secondary education	47/225 (21%)	18/100 (18%)	30/100 (30%)	0.238	95/425 (22%)
Secondary school complete	48/225 (21%)	16/100 (16%)	19/100 (19%)	0.677	83/425 (20%)
No formal schooling	16/225 (7%)	13/100 (13%)	4/100 (4%)	0.094	33/425 (8%)
College or higher	17/225 (8%)	3/100 (3%)	5/100 (5%)	0.346	25/425 (6%)
<b>Employment</b>					
Unemployed	82/225 (36%)	34/100 (34%)	32/100 (32%)	0.866	148/425 (35%)
Self-employed	56/225 (25%)	32/100 (32%)	35/100 (35%)	0.325	123/425 (29%)
Currently employed	65/225 (29%)	26/100 (26%)	18/100 (18%)	0.269	109/425 (26%)
Student	21/225 (9%)	6/100 (6%)	15/100 (15%)	0.153	42/425 (10%)
Retired	1/225 (0%)	2/100 (2%)	0/100 (0%)	0.280	3/425 (1%)

<b>Toilet facilities</b>					
Pit latrine with slab +/- foot rest	104/225 (46%)	25/100 (25%)	35/100 (35%)	0.039	164/425 (39%)
Pit latrine with slab and cover +/- foot rest	45/225 (20%)	19/100 (19%)	55/100 (55%)	<0.001	119/425 (28%)
Hanging toilet/latrine	59/225 (26%)	48/100 (48%)	9/100 (9%)	<0.001	116/425 (27%)
Flush Toilet (any type)	14/225 (6%)	5/100 (5%)	1/100 (1%)	0.118	20/425 (5%)
No toilet	2/225 (1%)	2/100 (2%)	0/100 (0%)	0.533	4/425 (1%)
Composting toilet	1/225 (0%)	1/100 (1%)	0/100 (0%)	0.720	2/425 (0%)
<b>Main water source</b>					
Public tap/standpipe	51/225 (23%)	8/100 (8%)	66/100 (66%)	<0.001	125/425 (29%)
Piped outside dwelling	69/225 (31%)	37/100 (37%)	9/100 (9%)	<0.001	115/425 (27%)
Tube well/borehole	64/225 (28%)	35/100 (35%)	15/100 (15%)	0.032	114/425 (27%)
Piped into dwelling	30/225 (13%)	11/100 (11%)	7/100 (7%)	0.353	48/425 (11%)
Unprotected well/spring	5/225 (2%)	6/100 (6%)	2/100 (2%)	0.181	13/425 (3%)
Surface water (including rainwater collection)	4/225 (2%)	2/100 (2%)	0/100 (0%)	0.556	6/425 (1%)
Tube well with powered pump	2/225 (1%)	1/100 (1%)	1/100 (1%)	1.000	4/425 (1%)
Treat water with chlorine	19/225 (8%)	5/100 (5%)	0/100 (0%)	0.004	24/425 (6%)
<b>No. household members</b>					
Children	2.0 (1.0-3.0)	2.0 (1.0-3.0)	2.0 (1.0-3.0)	0.395	2.0 (1.0-3.0)
Adults	2.0 (2.0-3.0)	3.0 (2.0-4.0)	2.0 (2.0-4.0)	0.907	3.0 (2.0-4.0)
<b>Electricity</b>					
Electricity available in house	119/225 (53%)	41/100 (41%)	58/100 (58%)	0.357	218/425 (51%)
<b>Main cooking fuel</b>					
Charcoal	161/225 (72%)	63/100 (63%)	88/100 (88%)	0.291	312/425 (73%)
Wood	61/225 (27%)	35/100 (35%)	11/100 (11%)	0.004	107/425 (25%)
Electricity	3/225 (1%)	2/100 (2%)	1/100 (1%)	0.869	6/425 (1%)
<b>Animals at home?</b>					
Any animal	71/225 (32%)	43/100 (43%)	15/100 (15%)	0.004	129/425 (30%)
Poultry	46/71 (65%)	34/43 (79%)	10/15 (67%)	0.800	90/129 (70%)
Dogs	18/71 (25%)	11/43 (26%)	9/15 (60%)	0.201	38/129 (29%)
Other	11/71 (15%)	9/43 (21%)	5/15 (33%)	0.413	25/129 (19%)
Goats	12/71 (17%)	7/43 (16%)	1/15 (7%)	0.830	20/129 (16%)
Cattle	2/71 (3%)	3/43 (7%)	0/15 (0%)	0.406	5/129 (4%)

*Note:*

ART = Antiretroviral therapy, CPT = Co-trimoxazole preventative therapy, EFV: Efavirenz, 3TC: Lamivudine, TDF: Tenofovir. Numeric values are median (IQR)) unless otherwise stated. P-values are to assess for differenced across the three groups: Fisher's exact test across the groups for categorical variable, and Kruskal-Wallace test for continuous variables.

\* ART status includes HIV reactive only as denominator

† Missing CPT data for two participants.

### 5.4.2 Exposures during the study period

Exposures to antimicrobials and hospitalisation of the cohort are shown in Figures 5.3 and 5.4 and Table 5.2. Antimicrobial-unexposed inpatients (Arm 2 participants) had a shorter length of hospital stay than participants with sepsis (median [IQR] 2 [2-7] versus 5 [2-10] days,  $p = 0.002$  by Kruskal-Wallis test). Five of the 100 Arm 2 participants were taking co-trimoxazole preventative therapy (CPT) at baseline, 18 received further courses of antimicrobials during the study period, and two were started on TB therapy. Some participants received combinations of these therapies, so in total 23% (23/100) Arm 2 participants received an antibacterial during the study period, most commonly within 30 days following enrollment (Figure 5.4).

Both antimicrobial exposure and hospitalisation were unusual in the community cohort; 7% (7/100) community (Arm 3) participants were taking CPT and one received a 5-day course of amoxicillin meaning that 8% (8/100) Arm 3 participants received an antibacterial during the study period. In addition one Arm 3 participant was hospitalised for 1 day in the study period.

The most commonly received antibacterial by participants with sepsis (apart from co-trimoxazole and TB therapy) was ceftriaxone by some distance with 998 participant-days of exposure in 189 participants during the study period, and a median 5 (IQR 3-7) day course on admission. Ciprofloxacin and amoxicillin were also commonly received, with 61 participants receiving 398 participant-days of exposure to ciprofloxacin with a median 7 (IQR 5-7) day course, and 39 participants receiving 235 participant-days of exposure to amoxicillin with a median 5 (IQR 5-7) day course. Because of the chronic nature of the therapy, the greatest exposure (in terms of participant-days) were to co-trimoxazole and TB therapy, by an order of magnitude.




Figure 5.3: Hospital and antibacterial exposure of participants expressed as (A) proportion of participants in the sepsis (arm 1) and inpatient antimicrobial-unexposed (arm 2) groups who are hospitalised and exposed to the most commonly received antibacterials, as a function of time and (B) participant-days of exposure to the most commonly received antibacterials (excluding TB therapy and co-trimoxazole) across the three arms of the study over the whole study period.

Table 5.2: Antimicrobial and hospital exposure stratified by arm

Exposure	Number exposed			Exposure (person-days)			Median (IQR) exposure length (days)		
	Arm 1	Arm 2	Arm 3	Arm 1	Arm 2	Arm 3	Arm 1	Arm 2	Arm 3
Total At Risk	225	100	100	33797	14336	21983	-	-	-
<b>Exposures</b>									
Hospitalised	225	100	1	1727 (5%)	500 (3%)	1 (<1%)	5 (2-10)	2 (2-7)	1 (1-1)
Cotrimoxazole	110	6	7	14447 (43%)	549 (4%)	1388 (6%)	180 (27-190)	86 (6-177)	190 (183-206)
TB therapy	52	2	0	6843 (20%)	291 (2%)	0 (0%)	178 (58-180)	146 (133-158)	-
Ceftriaxone	183	7	0	997 (3%)	26 (<1%)	0 (0%)	5 (3-7)	3 (2-4)	-
Ciprofloxacin	61	2	0	398 (1%)	12 (<1%)	0 (0%)	7 (5-7)	6 (6-6)	-
Amoxicillin	38	3	1	235 (1%)	21 (<1%)	5 (<1%)	7 (5-7)	5 (5-8)	5 (5-5)
Metronidazole	24	2	0	148 (<1%)	10 (<1%)	0 (0%)	6 (2-7)	5 (5-5)	-
Fluconazole	27	0	0	118 (<1%)	0 (0%)	0 (0%)	3 (2-5)	-	-
Aciclovir	2	0	0	47 (<1%)	0 (0%)	0 (0%)	24 (16-31)	-	-
Co-amoxiclav	10	2	0	40 (<1%)	12 (<1%)	0 (0%)	5 (2-5)	6 (6-6)	-
Erythromycin	5	0	0	38 (<1%)	0 (0%)	0 (0%)	7 (5-11)	-	-
Doxycycline	7	0	0	34 (<1%)	0 (0%)	0 (0%)	3 (2-6)	-	-
Artesunate	11	0	0	25 (<1%)	0 (0%)	0 (0%)	2 (2-3)	-	-
LA	7	0	0	19 (<1%)	0 (0%)	0 (0%)	3 (2-3)	-	-
Streptomycin	2	0	0	16 (<1%)	0 (0%)	0 (0%)	8 (7-9)	-	-
Gentamicin	4	0	0	15 (<1%)	0 (0%)	0 (0%)	4 (3-5)	-	-
Amphotericin	2	0	0	8 (<1%)	0 (0%)	0 (0%)	4 (4-4)	-	-
Azithromycin	2	2	0	7 (<1%)	12 (<1%)	0 (0%)	4 (3-4)	6 (6-6)	-
Penicillin	2	0	0	5 (<1%)	0 (0%)	0 (0%)	2 (2-3)	-	-
Flucloxacillin	2	0	0	5 (<1%)	0 (0%)	0 (0%)	2 (2-3)	-	-
Chloramphenicol	1	0	0	1 (<1%)	0 (0%)	0 (0%)	1 (1-1)	-	-
Quinine	1	0	0	1 (<1%)	0 (0%)	0 (0%)	1 (1-1)	-	-

*Note:*

TB = tuberculosis. Median exposure length includes only those exposed. Total at risk shows the total number of participants and participant-days of follow up included in the study.




Figure 5.4: Cumulative number of arm 2 participants exposed to antibacterials (including CPT and TB therapy) as a function of time.

#### 5.4.3 ESBL-E colonisation

#### 5.4.4 Determinants of baseline ESBL colonisation

#### 5.4.5 Determinants of d28 ESBL-E acquisition

### 5.5 Discussion

#### 5.5.1 Limitations

### 5.6 Conclusions and further work



## Chapter 6

# Whole genome sequencing of ESBL *E. coli* carriage isolates

Placeholder



## 6.1 Chapter overview

## 6.2 Methods

### 6.2.1 Bioinformatic pipeline

### 6.2.2 Global *E. coli* collection

### 6.2.3 Statistical analysis

## 6.3 Results

### 6.3.1 Samples and quality control

### 6.3.2 Phylogroup, MLST and core genome phylogeny of study isolates

### 6.3.3 Study isolates in a global context

### 6.3.4 Antimicrobial resistance determinants

#### 6.3.4.1 $\beta$ -lactam resistance

#### 6.3.4.2 Quinolone resistance

#### 6.3.4.3 Aminoglycoside resistance

#### 6.3.4.4 Chloramphenicol, co-trimoxazole, tetracycline and other resistance determinants

#### 6.3.4.5 Clustering and lineage association of AMR determinants

### 6.3.5 Plasmid replicons

### 6.3.6 Testing metadata associations: SNP distance, hierBAPS sequence clusters and ESBL-clusters

#### 6.3.6.1 Hierarchical BAPS clustering of core gene pseudosequences

#### 6.3.6.2 ESBL-clusters

#### 6.3.6.3 Assessing for healthcare-associated lineages

#### 6.3.6.4 Assessing for within-patient conservation of lineage or MGE

## 6.4 Discussion



## Chapter 7

# Gut mucosal carriage of ESBL-E in Blantyre, Malawi



## References